|Bid||48.38 x 1300|
|Ask||51.24 x 1000|
|Day's range||51.04 - 51.43|
|52-week range||40.00 - 51.84|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||26.41|
|Forward dividend & yield||1.74 (3.40%)|
|1y target est||55.25|
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.
The Zacks Analyst Blog Highlights: JPMorgan, Sanofi, General Electric, American Electric Power and Shopify
Drugmakers including Pfizer Inc , GlaxoSmithKline PLC and Sanofi SA are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the price increases will be below 10%, and around half of them are in the range of 4 to 6%, said 3 Axis co-founder Eric Pachman. More price increases are expected to be announced later this week, which could affect the median and range.
This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.
Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Shares in Sanofi rose on Tuesday after the French drugmaker said it would focus on vaccines and treatments like its promising eczema medicine Dupixent to grow sales, in a business revamp seen as potentially leading to spin-offs. Like rivals from Britain's GlaxoSmithKline to Switzerland's Novartis , the company, which also announced cost savings targets and a goal to boost margins, is trying to zoom in on potential blockbuster drugs. Sanofi is gathering investors in Cambridge, Massachusetts, to discuss ways to improve performance.